Synjardy is owned by Boehringer Ingelheim.

Synjardy contains Empagliflozin; Metformin Hydrochloride.

Synjardy has a total of 14 drug patents out of which 0 drug patents have expired.

Synjardy was authorised for market use on 26 August, 2015.

Synjardy is available in tablet;oral dosage forms.

Synjardy can be used as method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin, method for reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin, method for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure and type 2 diabetes mellitus by administration of empagliflozin, treating type 2 diabetes mellitus by assessing renal function and orally administering empagliflozin in a daily amount of 10 mg or 25 mg if the egfr is >=30 ml/min/1.73 m2 and <60 ml/min/1.73 m2, wherein the treatment improves glycemic control, method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2.

Drug patent challenges can be filed against Synjardy from 20 December, 2025.

The generics of Synjardy are possible to be released after 17 November, 2034.